Singleron Biotechnologies & IHLAD launch Joint Venture to advance precision medicine in Middle East

The Institute for Healthier Living Abu Dhabi (IHLAD), the world’s first specialised Healthy Longevity Medicine Centre, and Singleron Biotechnologies, a global leader in single-cell multi-omics technologies, has announced the formation of AD-Omics, a groundbreaking joint venture designed to revolutionise precision medicine diagnostic offerings across the Middle East.

AD-Omics will focus on implementing cutting-edge genomic and single-cell multi-omics technologies to deliver personalised healthcare solutions for the first time in the region, in alignment with the UAE’s vision of becoming a global leader in advanced healthcare, fostering innovation, and enhancing patient outcomes.

This strategic collaboration will combine IHLAD’s expertise in scientific healthy longevity with Singleron’s innovative technologies in single cell multi-omics to address the unique healthcare needs of the region.

Key areas of collaboration will include:

• Genomic and cellular insights: Bringing Singleron’s advanced single-cell sequencing technologies to the region for the first time to advance insights in research and ageing together with future clinical offerings.
• Chronic disease management: Enhancing the diagnosis and treatment of chronic illnesses such as diabetes, cardiovascular diseases, and cancer through precision medicine.
• Education and research: Establishing regional centers of excellence to train healthcare professionals and foster research in precision medicine.
• AI integration: Using artificial intelligence to analyse multi-omics data and develop predictive models for disease progression and treatment outcomes.
• Market development: Providing the Middle East region with advanced single cell multi-omics solutions, from products to end-to-end service.